RSVIG-IV: Completed patient accrual for a Phase III PREVENT trial in 510 infants born prematurely or who have bronchopulmonary dysplasia, and in a Phase III car

MedImmune Inc. (MEDI), Gaithersburg, Md. Product: RSVIG-IV, an intravenous hyperimmune globulin derived from human plasma enriched in antibodies for respiratory syncytial virus Indication: Infants at ...